Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Immune Checkpoint Inhibitors in Gliomas

(2017) Aaron C. Tan et al.   Current Oncology Reports

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells

(2017) Jonas R.M. Van Audenaerde et al.   Oncotarget

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells

(2016) Heleen H. Van Acker et al.   Journal of Hematology & Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013

(2016) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma

(2016) Zheng Wang et al.   OncoImmunology

Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma

(2016) Elly Marcq et al.   OncoImmunology

Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer

(2015) Parvin Forghani et al.   BREAST CANCER RESEARCH AND TREATMENT

TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells

(2015) Marianne Boes et al.   CANCER LETTERS

Targeting immune checkpoints: New opportunity for mesothelioma treatment?

(2015) Elly Marcq et al.   CANCER TREATMENT REVIEWS

Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

(2015) Dimitrios Mathios et al.   INTERNATIONAL JOURNAL OF CANCER

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs

(2015) Rachid Ammi et al.   PHARMACOLOGY & THERAPEUTICS

Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice

(2015) Stefano Garofalo et al.   Nature Communications

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

(2015) Victor Ho et al.   Oncotarget

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

(2015) Paul A. Beavis et al.   Cancer Immunology Research

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

(2015) D. A. Reardon et al.   Cancer Immunology Research

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner

(2015) Sébastien Anguille et al.   PLoS One

Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma

(2014) S Han et al.   BRITISH JOURNAL OF CANCER

Combinatorial Immunotherapy of Polyinosinic–Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors

(2014) Toshihiro Nagato et al.   CLINICAL CANCER RESEARCH

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

The Chemokine Receptor CXCR3 Is Degraded following Internalization and Is Replenished at the Cell Surface by De Novo Synthesis of Receptor

(2014) A. Meiser et al.   JOURNAL OF IMMUNOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling

(2014) Nicolas Goffart et al.   NEURO-ONCOLOGY

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells

(2014) Hatem Soliman et al.   PLoS One

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

(2014) I. Melero et al.   Cancer Discovery

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level

(2013) Justyna Kmiecik et al.   JOURNAL OF NEUROIMMUNOLOGY

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma

(2013) Martin Glas et al.   STEM CELLS

Dynamics of Transforming Growth Factor Beta Signaling in Wound Healing and Scarring

(2013) Kenneth W. Finnson et al.   Advances in Wound Care

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

(2012) G. Erdag et al.   CANCER RESEARCH

Toll-Like Receptor 3 Ligand Polyinosinic:Polycytidylic Acid Promotes Wound Healing in Human and Murine Skin

(2012) Qing Lin et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines

(2011) A. Kuznik et al.   JOURNAL OF IMMUNOLOGY

Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation

(2011) Tim Kees et al.   NEURO-ONCOLOGY

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners

(2010) Xinmei Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival

(2010) Isaac Yang et al.   JOURNAL OF CLINICAL NEUROSCIENCE

CCR5 Ligands Modulate CXCL12-Induced Chemotaxis, Adhesion, and Akt Phosphorylation of Human Cord Blood CD34+ Cells

(2009) S. Basu et al.   JOURNAL OF IMMUNOLOGY

Twelve immunotherapy drugs that could cure cancers

(2008) Martin A. ‘Mac’ Cheever   IMMUNOLOGICAL REVIEWS